A multicenter, randomized, double-blind, placebo-controlled Phase 3 study (APPARENT) to assess the efficacy and safety of iptacopan in idiopathic (primary) immune complex-mediated membranoproliferative glomerulonephritis
Nicholas J A Webb, UdayKiran Veldandi, David Kavanagh, Marina Vivarelli, Andrew Bomback, Yaqin Wang, Matthias Meier, Richard J H Smith